홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

테노포비르

Tenofovir

HCID 464205
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
147127-20-6
표준 SMILES
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
InChIKey
SGOIRFVFHAKUTI-ZCFIWIBFSA-N
분자식
C9H14N5O4P
평균 분자량
287.21 g/mol
단동위원소 질량
287.07834094

개요

Tenofovir (anhydrous) is a member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as an antiviral drug, a drug metabolite and a HIV-1 reverse transcriptase inhibitor. It is a member of phosphonic acids and a nucleoside analogue. It is a conjugate acid of a tenofovir(1-).

이름 및 식별자

우선 이름
Tenofovir
IUPAC
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
현지명
테노포비르
영어명
Tenofovir
분자식
C9H14N5O4P
분자량
287.21

이름 및 동의어

Tenofovir147127-20-6(R)-9-(2-Phosphonomethoxypropyl)adenine(R)-PMPAtenofovir (anhydrous)Tenofovir anhydrousGS-1275anhydrous tenofovirtenofovir (anh.)GS-1278CHEBI:63625({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
이름 더 보기
테노포비르(R)-9-(2-PHOSPHONYLMETHOXYPROPYL)-ADENINEVireadApropovir9-PmpaGS 1275Tenofovienofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acidW4HFE001U5(R)-9-(Phosphonomethoxypropyl)adeninePMP-ADTXSID9040132(((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid(R)-9-(2-Phosphonylmethoxypropyl)adeninePhosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-

데이터베이스 식별자

CAS
147127-20-6
PubChem CID
464205
DTXSID
DTXSID9040132
ChEMBL
CHEMBL3989702、CHEMBL483
ChEBI
CHEBI:63625
UNII
W4HFE001U5
EC Number
604-571-2
Nikkaji
J540.142I

물성

구조 계산 물성보충 중

XLogP
-1.6
극성 표면적
136 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
8
회전 가능 결합 수
5
무거운 원자 수
19
형식 전하
0
복잡도
354

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Metabolite of Tenofovir alafenamide, 'Tenofovir disoproxil

LogP-1.6
Solubility1.87e+00 g/L
Human DrugsFDA approved drugs -> Active ingredient
Melting Point276 - 280 °C
Physical DescriptionSolid
Dissociation Constants3.8 and 6.7

물리화학적 성질

녹는점
276 · 276-280°C
끓는 점
616.1 · 616.1±65.0 °C(Predicted)
밀도
1.79 · 1.79±0.1 g/cm3(Predicted)
저장 조건
-20 °C · -20°C
용해도
산성수(약간 용해됨), DMSO(약간 용해됨, 가열), 물(약간 용해됨, 가열)
산도 계수 (pKa)
2.36 · 2.36±0.10(Predicted)
물리적 상태
가루
색상
흰색에서 베이지색
수용성
13.4 mg/mL · 13.4mg/mL(25℃)
Merck
14 · 14,9146
InChI
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
InChIKey
SGOIRFVFHAKUTI-ZCFIWIBFSA-N
SMILES
P(CO[C@H](C)CN1C2C(N=C1)=C(N)N=CN=2)(=O)(O)O

화학적 성질

White Crystalline Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H318 (100%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

P264+P265, P280, P305+P354+P338, and P317 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory InformationREACH registered substance: (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid (EC: 604-571-2)
Hazard Classes and CategoriesEye Dam. 1 (100%)

독성 정보

Hepatotoxicity · 1건

Like all nucleoside analogues used as therapy of hepatitis B, tenofovir can cause transient increases in serum aminotransferases during or after therapy. These abnormalities appear to be due to an exacerbation or flare of the underlying hepatitis B. Three types of flares due to nucleoside analogue therapy have been described: transient flares during initiation of therapy (treatment flares), flares occurring in association with development of antiviral resistance (breakthrough flares) and flares occurring in the few months after stopping therapy (withdrawal flares). Treatment flares generally arise during the first few months of starting therapy, are usually mild, asymptomatic and self-limited and do not require dose modification or interruption of therapy. Breakthrough flares generally follow the development of antiviral resistance and subsequent rise in HBV DNA levels during nucleoside analogue therapy. Breakthrough flares can be symptomatic and severe. Because tenofovir is associated with a very low rate of antiviral resistance (

Drug Induced Liver Injury · 6건

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

tenofovir

Viread®

Antivirals

8

most-DILI-concern

EPA Human Health Benchmarks for Pharmaceuticals · 6건

Tenofovir

0.6

2.5

The recommended dosage of tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 25 mg/day, Lowest Therapeutic Dose (LTD): 0.3 mg/kg-day, and Screening Dose: 0.0001 mg/kg-day.

21-Sep-21

안전 데이터

wgk
WGK 3
rtecs
SZ6563600
HS 번호
29339900
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

Protein BindingTenofovir is minimally bound to plasma proteins and only about 7.2% of the administered dose is found in the bound state.
Pharmacodynamics · 1건

Tenofovir has been shown to be highly effective in patients that have never had an antiretroviral therapy and it seemed to have lower toxicity than other antivirals such as [stavudine]. In phase 3 clinical trials, tenofovir presented a similar efficacy than [efavirenz] in treatment-naive HIV patients. In hepatitis B infected patients, after one year of tenofovir treatment, the viral DNA levels were undetectable.

Mechanism of Action · 1건

Once tenofovir is activated by a bi-phosphorylation it acts as an antiviral acyclic nucleoside phosphonate. It is a potent inhibitor of the viral reverse transcriptase with an inhibitory constant of approximately 0.022 micromolar. Once activated, tenofovir acts with different mechanisms including the inhibition of viral polymerase causing chain termination and the inhibition of viral synthesis. All these activities are attained by its competition with deoxyadenosine 5'-triphosphate in the generation of new viral DNA. Once tenofovir is incorporated in the chain, it induces a chain termination which in order inhibits viral replication. The safety of tenofovir relies on its low affinity towards the cellular DNA polymerase including the mitochondrial DNA polymerase gamma.

Biological Half-LifeThe reported half-life of tenofovir is of 32 hours.
Metabolism/MetabolitesTenofovir activation is performed by a bi-phosphorylation which in order forms the biologically active compound, tenofovir biphosphate. This metabolic activation has been shown to be performed in hepG2 cells and human hepatocytes.
FDA Pharmacological Classification · 6건

W4HFE001U5

TENOFOVIR ANHYDROUS

Established Pharmacologic Class [EPC] - Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Established Pharmacologic Class [EPC] - Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Chemical Structure [CS] - Nucleosides

Mechanisms of Action [MoA] - Nucleoside Reverse Transcriptase Inhibitors

MeSH Pharmacological Classification · 3건

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Absorption, Distribution and Excretion · 4건

Tenofovir as the active moiety presents a very low bioavailability when orally administered. Hence, the administration of this active agent is required to be under its two prodrug forms, [tenofovir disoproxil] and [tenofovir alafenamide]. This reduced absorption is suggested to be related to the presence of two negative charges among its structure. This negative charge limits its cellular penetration, and its passive diffusion across cellular membranes and intestinal mucosa hindering its availability for oral administration. Intravenous tenofovir has been shown to produce a maximum plasma concentration of 2500 ng/ml with an AUC of 4800 ng.h/ml.

Tenofovir is eliminated in the urine by tubular secretion and glomerular filtration. The elimination of this compound is driven by the activity of the human organic anion transporters 1 and 3 and its secretion is mainly ruled by the activity of the multidrug resistance-associated protein 4.

Accumulation of tenofovir in plasma is related to the presence of nephrotoxic effects. It is reported that tenofovir presents a volume of distribution of 0.813 L/kg.

The clearance of tenofovir is highly dependent on the patient renal stage and hence the clearance rate in patients with renal impairment is reported to be of 134 ml/min while in patients with normal function the clearance rate can be of 210 ml/min.

Cellular LocationsCytoplasm
Metabolite PathwaysTenofovir Action Pathway
응용 분야 · 3건

개요Tenofovir is an analog of adenosine monophosphate that has antiviral activity. It is converted by cellular enzymes to tenofovir diphosphate, an obligate chain terminator that inhibits the activity of HIV reverse transcriptase and hepatitis B virus polymerase. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α and β and mitochondrial DNA polymerase γ. For in vivo and cell culture use, tenofovir is supplied as a water soluble prodrug in the form of tenofovir disoproxil (fumarate) , which increases the intracellular diphosphorylated compound >1,000-fold above the level attained with unmodified tenofovir.

역사Tenofovir was developed in the 1980s by Professor Antonín Holý and his team at the Institute of Organic Chemistry and Biochemistry (IOCB Prague) of the Czech Academy of Sciences. Their research focused on the design and synthesis of nucleotide analogs, aiming to develop novel compounds with antiviral activity. As an acyclic nucleotide phosphate analog, tenofovir exhibited broad-spectrum antiviral potential in vitro, but its low oral bioavailability limited its initial development. To overcome this bottleneck, collaboration with Gilead Sciences was crucial, ultimately leading to the successful development of tenofovir disoproxil fumarate (TDF) through a prodrug synthesis strategy. This prodrug was first approved by the FDA in 2001 for the treatment of HIV-1 infection, marking a significant breakthrough in its clinical application. Subsequent research further solidified its position in the treatment of chronic hepatitis B and facilitated the market launch of tenofovir alafenamide (TAF), a prodrug with superior renal and bone safety characteristics.

용도Tenofovir is a drug used for the treatment of chronic heptatitis B as well as prevention and treatment of HIV/AIDS. It is a kind of nucleotide analog, acting as the reverse-transcriptase inhibitor (NtRTI). It inhibits the activity of HIV reverse transcriptase through competing with the natural substrate deoxyadenosine 5’-triphosphate, causing the termination of DNA chain.

상·하류 제품 정보

상류 원료

Para-포름알데하이드디에틸 카보네이트디에틸포스파이트

하류 제품

phenyl hydrogen ((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate[2-(6-AMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-4-Morpholinylphosphinic Acid테노포비어디소프록실푸마레이트
추가 설명 · 1건

정의ChEBI: A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxy ethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.

관련 반응

8건
반응 기록 만들기
HRID 133116 반응식
HRID 133116반응물로
HRID 554463 반응식
HRID 554463생성물로
HRID 554464 반응식
HRID 554464생성물로
HRID 581681 반응식
HRID 581681생성물로
HRID 1600580 반응식
HRID 1600580생성물로
HRID 1716371 반응식
HRID 1716371반응물로
HRID 1716372 반응식
HRID 1716372생성물로
HRID 1890236 반응식
HRID 1890236생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트